Uppsala, Sweden: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Cygnus Technologies Inc. has launched a third immunoassay kit specifically designed for compatibility with the company’s Gyrolab™ xP workstation. The new kit enables scientists to test for the presence of Protein A, an impurity that can occur in any antibody-based therapeutic that has been purified using affinity chromatography. Two Host Cell Proteins (HCP) Kits are already available for detecting impurities from E.coli or CHO cells during bioprocess development and production.

Scientists optimizing purification processes and working in process control, routine QC and product release testing can now accelerate assay development timelines and maximize productivity through the convenience of three, ready-to-use kits and the automated immunoassay platform from Gyros.

Ken Hoffmann, President at Cygnus Technologies, explained: “At Cygnus we specialize in providing analytical products for testing biologics and their impurities. By continually adding to our range of kits compatible with this assay platform we will enable our customers to further increase the productivity of their labs.”

Commenting on the announcement, Erik Walldén, CEO at Gyros, added: “Biopharmaceutical companies and their service providers, CROs and CMOs, already use our platform to increase the efficiency of their workflows. For example, users of Gyrolab workstations have cut assay development times down to days compared to the weeks required for conventional techniques. Application-specific kits from independent suppliers strengthen our offering and demonstrate the acceptance of our nanoliter-scale immunoassay platform within the industry.”

Kits will be sold and supported through Cygnus Technologies.

ENDS

Notes to Editors

Enquiries:

Lorna Cuddon

Zyme Communications Ltd

Tel: +44 (0) 7811 996 942

Skype: lorna..cuddon

Email: lorna..cuddon@zymecommunications.com

www.zymecommunications.com

About Gyros AB https://www.gyros.com

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.

For more information about Cygnus Technologies please visit: www.cygnustechnologies.com